SCHEMBL8626304

SCHEMBL8626304

CC(C)=CCC/C(C)=C/CC/C(C)=C/CC(C/C=C(\C)CC/C=C(\C)CCC=C(C)C)CCI

nearest known ligand 0.55

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.55
FNTA P49354 1/20 0.54
FNTB P49356 1/20 0.54
MAPT P10636 2/20 0.50
MEN1 O00255 2/20 0.50
CYP3A4 P08684 2/20 0.50
ALOX15 P16050 2/20 0.50
ALDH1A1 P00352 1/20 0.50
UGT1A1 P22309 1/20 0.50
SQLE Q14534 5/20 0.48
KDM4E B2RXH2 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8622485 0.85 KMT2A (0.59) KMT2AFNTAFNTBMAPTMEN1
SCHEMBL8620659 0.84 SQLE (0.60) KMT2AFNTAFNTBMAPTMEN1
SCHEMBL14249299 0.81 SQLE (0.57) KMT2AFNTAFNTBMAPTMEN1
SCHEMBL8619405 0.79 KMT2A (0.61) KMT2AFNTAFNTBMAPTMEN1
SCHEMBL9304561 0.78 KMT2A (0.73) KMT2AFNTAFNTBMAPTMEN1
SCHEMBL16671458 0.78 KMT2A (0.73) KMT2AFNTAFNTBMAPTMEN1
SCHEMBL4572068 0.78 KMT2A (0.73) KMT2AFNTAFNTBMAPTMEN1
SCHEMBL9304569 0.78 KMT2A (0.73) KMT2AFNTAFNTBMAPTMEN1
SCHEMBL8850354 0.77 KMT2A (0.64) KMT2AFNTAFNTBMAPTMEN1
SCHEMBL8623413 0.75 KMT2A (0.67) KMT2AFNTAFNTBMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5712396-A PHOSPHONOSULFONATE COMPOUNDS USED FOR INHIBITING CHOLESTEROL BIOSYNTHESIS AND ATHEROSCLEROSIS MAGNIN DAVID R (US) 1998-01-27 US disclosed
US-5567841-A ANTICHOLESTEROL AGENT BRISTOL-MYERS SQUIBB COMPANY (US) 1996-10-22 US disclosed
US-5470845-A Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia BRISTOL-MYERS SQUIBB COMPANY (US) 1995-11-28 US disclosed